Related Experiment Video

Updated: Oct 1, 2025

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel
08:29

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel

Published on: May 14, 2018

10.1K

Low-dose paclitaxel modulates the cross talk between the JNK and Smad signaling in primary biliary fibroblasts

Jiamei Lu1, Liang Yu2, Jianhua Shi2

  • 1The Second Affiliated Hospital of Xi'an Jiaotong University, Department of Nephrology - Xi'an, China.

Revista Da Associacao Medica Brasileira (1992)
|March 3, 2022
PubMed
Abstract

Insights

Transforming growth factor beta 1 activates JNK/Smad2L, leading to benign bile duct stricture via collagen overexpression. Low-dose paclitaxel may prevent this by inhibiting JNK/Smad2L phosphorylation.

Area of Science:

  • Gastroenterology and Hepatology
  • Molecular Biology
  • Oncology

Background:

  • Benign bile duct stricture (BBDS) pathogenesis involves complex molecular signaling.
  • Fibroblast activation and extracellular matrix deposition are key features of BBDS.

Purpose of the Study:

  • To elucidate the molecular mechanisms of BBDS.
  • To investigate low-dose paclitaxel as a potential therapeutic agent for BBDS prevention.

Main Methods:

  • Primary fibroblasts were stimulated with transforming growth factor beta 1 (TGF-β1).
  • Expression of collagen type I (COL1) and connective tissue growth factor (CTGF) was measured.
  • Western blot analysis detected phosphorylation of JNK and Smad2L.
  • Effects of low-dose paclitaxel on TGF-β1-induced changes were assessed.

Main Results:

  • TGF-β1 stimulated COL1 and CTGF secretion and JNK phosphorylation in biliary fibroblasts.
  • JNK inhibition or Smad2 knockdown attenuated TGF-β1-induced COL1 and CTGF secretion.
  • Low-dose paclitaxel inhibited TGF-β1-induced COL1 expression and potentially collagen secretion.

Conclusions:

  • TGF-β1-induced JNK/Smad2L activation drives BBDS through COL1 and CTGF overexpression.
  • Low-dose paclitaxel demonstrates potential in inhibiting the JNK/Smad2L pathway, offering a preventive strategy for BBDS.

More Related Videos

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles08:02

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

5.9K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.2K

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.5K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.6K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.9K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.9K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.9K